WO2002003977A3 - Combinations of statins, estrogenic agents and optionally estrogens - Google Patents

Combinations of statins, estrogenic agents and optionally estrogens Download PDF

Info

Publication number
WO2002003977A3
WO2002003977A3 PCT/US2001/021085 US0121085W WO0203977A3 WO 2002003977 A3 WO2002003977 A3 WO 2002003977A3 US 0121085 W US0121085 W US 0121085W WO 0203977 A3 WO0203977 A3 WO 0203977A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
ethers
statins
combinations
esters
Prior art date
Application number
PCT/US2001/021085
Other languages
French (fr)
Other versions
WO2002003977A2 (en
Inventor
Simon Nicholas Jenkins
Barry Samuel Komm
Christopher Paul Miller
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Priority to BR0112365-3A priority Critical patent/BR0112365A/en
Priority to CA002414060A priority patent/CA2414060A1/en
Priority to EP01950826A priority patent/EP1359940A2/en
Priority to JP2002508432A priority patent/JP2004502731A/en
Priority to MXPA02012896A priority patent/MXPA02012896A/en
Priority to AU2001271785A priority patent/AU2001271785A1/en
Publication of WO2002003977A2 publication Critical patent/WO2002003977A2/en
Publication of WO2002003977A3 publication Critical patent/WO2002003977A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

This invention comprises methods of treating cardiovascular disorders and lowering blood LDL levels comprising administration of a statin, an estrogen and compound of the formulae (I or II): wherein Z is a moiety selected from the group of: (III) wherein: R1 is selected from H, OH or the C1-C12 esters or C1-C12 alkyl ethers thereof, benzyloxy, or halogen; or C1-C4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether; R2, R3, R4, R5, and R6 are H, OH or C1-C12 esters or C1-C12 alkyl ethers thereof, halogens, or C1-C4 halogenated ethers, cyano, C1-C6 alkyl, or trifluoromethyl, with the proviso that, when R1 is H1, R2 is not OH; Y is the moiety: (IV) R7 and R8 are alkyl or concatenated together to form an optionally substituted, nitrogen-containing ring; or a pharmaceutically acceptable salt thereof.
PCT/US2001/021085 2000-07-06 2001-06-29 Combinations of statins, estrogenic agents and optionally estrogens WO2002003977A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BR0112365-3A BR0112365A (en) 2000-07-06 2001-06-29 Combinations of statins, estrogens and optionally estrogens
CA002414060A CA2414060A1 (en) 2000-07-06 2001-06-29 Combinations of statins, estrogenic agents and optionally estrogens
EP01950826A EP1359940A2 (en) 2000-07-06 2001-06-29 Combinations of statins, estrogenic agents and optionally estrogens
JP2002508432A JP2004502731A (en) 2000-07-06 2001-06-29 Combinations of statins, estrogens and optional estrogens
MXPA02012896A MXPA02012896A (en) 2000-07-06 2001-06-29 Combinations of statins, estrogenic agents and optionally estrogens.
AU2001271785A AU2001271785A1 (en) 2000-07-06 2001-06-29 Combinations of statins, estrogenic agents and optionally estrogens

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21609600P 2000-07-06 2000-07-06
US21618400P 2000-07-06 2000-07-06
US60/216,184 2000-07-06
US60/216,096 2000-07-06

Publications (2)

Publication Number Publication Date
WO2002003977A2 WO2002003977A2 (en) 2002-01-17
WO2002003977A3 true WO2002003977A3 (en) 2003-09-04

Family

ID=26910656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/021085 WO2002003977A2 (en) 2000-07-06 2001-06-29 Combinations of statins, estrogenic agents and optionally estrogens

Country Status (8)

Country Link
EP (1) EP1359940A2 (en)
JP (1) JP2004502731A (en)
CN (1) CN1468110A (en)
AU (1) AU2001271785A1 (en)
BR (1) BR0112365A (en)
CA (1) CA2414060A1 (en)
MX (1) MXPA02012896A (en)
WO (1) WO2002003977A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006504409A (en) 2002-07-24 2006-02-09 チルドレンズ　ホスピタル　メディカル　センター Compositions and products containing enantiomeric equol and methods for their production
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
AU2003286781B2 (en) 2002-10-29 2009-05-21 Brigham Young University Use of equol for treating androgen mediated diseases
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
HUE055321T2 (en) 2015-10-01 2021-11-29 Olema Pharmaceuticals Inc Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs
MX2018007079A (en) 2015-12-09 2018-11-12 The Board Of Trustees Of Univ Of Illinois Benzothiophene-based selective estrogen receptor downregulators.
CN109641874A (en) 2016-05-10 2019-04-16 C4医药公司 C for target protein degradation3The glutarimide degron body of carbon connection
CN109562113A (en) 2016-05-10 2019-04-02 C4医药公司 Loop coil degron body for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EA201990187A1 (en) 2016-07-01 2019-07-31 Г1 Терапьютикс, Инк. PYRIMIDINE ANTIPROLIFERATION AGENTS
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
AU2018205262A1 (en) 2017-01-06 2019-07-11 G1 Therapeutics, Inc. Combination therapy for the treatment of cancer
CA3052810A1 (en) 2017-02-10 2018-08-16 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
AU2018291026B2 (en) 2017-06-29 2022-09-01 G1 Therapeutics, Inc. Morphic forms of GIT38 and methods of manufacture thereof
CN113453679A (en) 2018-12-20 2021-09-28 C4医药公司 Targeted protein degradation
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059969A1 (en) * 1998-05-15 1999-11-25 American Home Products Corporation Compositions comprising 2-phenyl-indole compounds and estrogen formulations
WO1999059581A1 (en) * 1998-05-15 1999-11-25 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059969A1 (en) * 1998-05-15 1999-11-25 American Home Products Corporation Compositions comprising 2-phenyl-indole compounds and estrogen formulations
WO1999059581A1 (en) * 1998-05-15 1999-11-25 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens

Also Published As

Publication number Publication date
EP1359940A2 (en) 2003-11-12
JP2004502731A (en) 2004-01-29
CN1468110A (en) 2004-01-14
MXPA02012896A (en) 2003-10-24
CA2414060A1 (en) 2002-01-17
AU2001271785A1 (en) 2002-01-21
WO2002003977A2 (en) 2002-01-17
BR0112365A (en) 2003-05-13

Similar Documents

Publication Publication Date Title
WO2002003977A3 (en) Combinations of statins, estrogenic agents and optionally estrogens
WO2002003976A3 (en) Combinations of bisphosphonates, estrogenic agents and optionally estrogens
WO2002003992A3 (en) Use of substituted indole compounds for treating prosthesis-related bone degeneration
WO2002003988A3 (en) Use of substituted indole compounds for treating neuropeptide y-related conditions
WO2002003986A3 (en) Use of substituted indole compounds for treating breast disorders
WO2002003987A3 (en) Pharmaceutical compositions of estrogenic agents
WO2002003989A3 (en) Use of substituted indole compounds for treating sphincter incontinence
WO2002003990A3 (en) Use of substituted insole compounds for treating excessive intraocular pressure
HRP20000726B1 (en) Quinoline derivatives
WO2002003991A3 (en) Use of substituted indole compounds for increasing nitric oxide synthase activity
IL105421A0 (en) Taxol derivatives
EP1040823A3 (en) Stable foam compositions
WO2002004418A3 (en) Methods of inhibiting uterotrophic effects of estrogenic agents
WO2001009103A3 (en) Imidazole antiproliferative agents
DK1299348T3 (en) Compounds and compositions for delivery of active agents
CA2331873A1 (en) Fumagillol derivatives and processes for preparing the same
YU1501A (en) Quinoline derivatives
MX9700883A (en) Substituted quinazoline derivatives.
MXPA04004674A (en) Cannabinoid receptor ligands.
NZ518296A (en) N-phenyl-1,2-dihydro-2-oxo-quinoline-3-carboxamide derivatives and their use in the treatment of breast and prostatic cancer
CA2313122A1 (en) Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents
ATE171188T1 (en) 4-AZASTEROIDS SUBSTITUTED IN THE 15 POSITION
KR20000005379A (en) Isatin derivatives as acetylcholinesterase inhibitors and analgesics
CA2302943A1 (en) Phthalazine compounds and therapeutic agents for erectile dysfunction
NZ506011A (en) Anti-tumour agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/012896

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2001950826

Country of ref document: EP

Ref document number: 2414060

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 018150896

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001950826

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001950826

Country of ref document: EP